Table of Content

1 Key Insights

2 Executive Summary of Alcohol Use Disorder (AUD)

3 SWOT Analysis for Alcohol Use Disorder (AUD)

4 Alcohol Use Disorder (AUD) Market Overview at a Glance
4.1 Market Share (%) Distribution of AUD in 2017
4.2 Market Share (%) Distribution of AUD in 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Definitions
5.3 Causes and risk factors
5.4 Subtypes of Alcoholics
5.5 Pathophysiology
5.6 Genetics of AUD
5.7 Diagnosis
5.8 Biomarkers

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Total Diagnosed Prevalent Population of Alcohol Use Disorder (AUD)

7 Country Wise-Epidemiology of Alcohol Use Disorder
7.1 The United States
7.1.1 Assumptions and Rationale
7.1.2 Diagnosed Prevalence of Alcohol Use Disorder (AUD) in the United States
7.1.3 Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States
7.1.4 Diagnosed Prevalence of AUD by Types in the United States
7.2 EU-5
7.2.1 Assumptions and Rationale
7.2.2 Germany
7.2.3 France
7.2.4 Italy
7.2.5 Spain
7.2.6 United Kingdom
7.3 Japan
7.3.1 Assumptions and Rationale
7.3.2 Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Japan
7.3.3 Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan
7.3.4 Diagnosed Prevalence of AUD by Types in Japan

8 Treatment of AUD
8.1 Guidelines
American Psychiatric Association Guidelines
NICE Guidelines
8.2 Case study: Naltrexone for the Management of Alcohol Dependence
8.3 Patient Journey

9 Unmet Needs

10 Marketed Therapies
10.1 Acamprosate: Merck sante
10.1.1 Product Description
10.1.2 Regulatory milestones
10.1.3 Clinical Development activity
10.1.4 Safety and Efficacy
10.2 Disulfiram: Odyssey pharmaceuticals
10.2.1 Product Description
10.2.2 Regulatory milestones
10.2.3 Clinical Development activity
10.3 Naltrexone: Dupont
10.3.1 Product Description
10.3.2 Regulatory milestones
Product development activity
10.3.3 Clinical Development activity
10.3.4 Safety and Efficacy

11 Emerging Therapies
11.1 Ibudilast: MediciNova
11.1.1 Product Description
11.1.2 Product Development Activities
11.1.3 Clinical Development
11.1.4 Safety and Efficacy
11.2 AD04: Adial Pharmaceuticals
11.2.1 Product Description
11.2.2 Product Development Activities
11.2.3 Clinical Development
11.2.4 Safety and Efficacy
11.3 TNX-102: Tonix Pharmaceuticals
11.3.1 Product Description
11.3.2 Product Development Activities

12 Alcohol Use Disorder: 7 Major Market Analysis
12.1 Key Findings
12.2 Market Outlook:7MM
12.3 Market Size of Alcohol Use Disorder (AUD) in 7MM
12.4 United States
12.4.1 Total Market size of Alcohol Use Disorder (AUD)
12.4.2 Alcohol Use Disorder (AUD) Market Size by Therapies
12.5 EU5 Countries
12.5.1 Germany
12.5.2 France
12.5.3 Italy
12.5.4 Spain
12.5.5 United Kingdom
12.5.6 Japan

13 Market Drivers

14 Market Barriers

15 Appendix
15.1 Report Methodology

16 DelveInsight Capabilities

17 Disclaimer

18 About DelveInsight



List of Figures


Figure 1: SWOT Analysis
Figure 2: Natural history of alcohol use disorders
Figure 3: Neuroimmune contributions to the cycle of addiction
Figure 4: Neuron-glia cell–cell interactions in neuroimmune responses to alcohol
Figure 5: AUDIT-C questionnaire
Figure 6: Diagnosed Prevalent Population of Alcohol Use Disorder (AUD) in 7MM (2017-2030)
Figure 7: Diagnosed Prevalence of AUD in the United States (2017-2030)
Figure 8: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States (2017-2030)
Figure 9: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by type in the United States (2017-2030)
Figure 10: Diagnosed Prevalence of AUD in Germany (2017-2030)
Figure 11: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Germany (2017-2030)
Figure 12: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Germany (2017-2030)
Figure 13: Diagnosed Prevalence of AUD in France (2017-2030)
Figure 14: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in France (2017-2030)
Figure 15: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in France (2017-2030)
Figure 16: Diagnosed Prevalence of AUD in Italy (2017-2030)
Figure 17: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Italy (2017-2030)
Figure 18: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Italy (2017-2030)
Figure 19: Diagnosed Prevalence of AUD in Spain (2017-2030)
Figure 20: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Spain (2017-2030)
Figure 21: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Spain (2017-2030)
Figure 22: Diagnosed Prevalence of AUD in United Kingdom (2017-2030)
Figure 23: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017-2030)
Figure 24: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in United Kingdom (2017-2030)
Figure 25: Diagnosed Prevalence of AUD in Japan (2017-2030)
Figure 26: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan (2017-2030)
Figure 27: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Japan (2017-2030)
Figure 28: Summary of available psychological treatments for AUD
Figure 29: Patient journey for Alcohol Use Disorder
Figure 30 Unmet needs for Alcohol Use Disorder
Figure 31: 7 Major Market Size of AUD in USD Million (2017–2030)
Figure 32: Market Size of AUD in the United States, USD Millions (2017–2030)
Figure 33: The US market size of AUD by therapies in USD Million (2017–2030)
Figure 34: Market Size of AUD in Germany, USD Millions (2017–2030)
Figure 35: Germany market size of AUD by therapies in USD Million (2017–2030)
Figure 36: Market Size of AUD in France, USD Millions (2017–2030)
Figure 37: France market size of AUD by therapies in USD Million (2017–2030)
Figure 38: Market Size of AUD in Italy, USD Millions (2017–2030)
Figure 39: Italy market size of AUD by therapies in USD Million (2017–2030)
Figure 40: Market Size of AUD in Spain, USD Millions (2017–2030)
Figure 41: Spain market size of AUD by therapies in USD Million (2017–2030)
Figure 42: Market Size of AUD in UK, USD Millions (2017–2030)
Figure 43: UK market size of AUD by therapies in USD Million (2017–2030)
Figure 44: Market Size of AUD in Japan, USD Millions (2017–2030)
Figure 45: Japan market size of AUD by therapies in USD Million (2017–2030)
Figure 46: Market Drivers
Figure 47 Market barriers for Alcohol Use Disorder

 

List of Tables


Table 1: Summary of Alcohol Use Disorder Market, Epidemiology, and Key Events (2017–2030)
Table 2: Diagnosed Prevalent Population of Alcohol Use Disorder (AUD) in 7MM (2017-2030)
Table 3: Prevalence of Alcohol Use Disorder (AUD) in the United States (2017-2030)
Table 4: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States (2017-2030)
Table 5: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in the United States (2017-2030)
Table 6: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Germany (2017-2030)
Table 7: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Germany (2017-2030)
Table 8: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Germany (2017-2030)
Table 9: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in France (2017-2030)
Table 10: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in France (2017-2030)
Table 11: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in France (2017-2030)
Table 12: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Italy (2017-2030)
Table 13: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Italy (2017-2030)
Table 14: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Italy (2017-2030)
Table 15: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Spain (2017-2030)
Table 16: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Spain (2017-2030)
Table 17: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Spain (2017-2030)
Table 18: Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017-2030)
Table 19: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017-2030)
Table 20: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in United Kingdom (2017-2030)
Table 21: Prevalence of Alcohol Use Disorder (AUD) in Japan (2017-2030)
Table 22: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan (2017-2030)
Table 23: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Japan (2017-2030)
Table 24: Ibudilast, Clinical Trial Description, 2020
Table 25: AD04, Clinical Trial Description, 2020
Table 26: 7 Major Market Size of AUD in USD Million (2017–2030)
Table 27: The US Market size of AUD in USD Million (2017–2030)
Table 28: The US market size of AUD by Therapies in USD Million (2017–2030)
Table 29: Germany Market size of AUD in USD Million (2017–2030)
Table 30: Germany market size of AUD by Therapies in USD Million (2017–2030)
Table 31: France Market size of AUD in USD Million (2017–2030)
Table 32: France market size of AUD by Therapies in USD Million (2017–2030)
Table 33: Italy Market size of AUD in USD Million (2017–2030)
Table 34: Italy market size of AUD by Therapies in USD Million (2017–2030)
Table 35: Spain Market size of AUD in USD Million (2017–2030)
Table 36: Spain market size of AUD by Therapies in USD Million (2017–2030)
Table 37: UK Market size of AUD in USD Million (2017–2030)
Table 38: UK market size of AUD by Therapies in USD Million (2017–2030)
Table 39: Japan Market size of AUD in USD Million (2017–2030)
Table 40: Japan market size of AUD by Therapies in USD Million (2017–2030)